サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536215

フェニルケトン尿症治療の世界市場

Phenylketonuria Treatment

出版日
ページ情報
英文 184 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
フェニルケトン尿症治療の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

フェニルケトン尿症治療の世界市場は2030年までに16億米ドルに達する見込み

2023年に9億7,500万米ドルと推定されるフェニルケトン尿症治療の世界市場は、分析期間2023～2030年にCAGR 7.0%で成長し、2030年には16億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるパリンジークドラッグは、CAGR 7.4%を記録し、分析期間終了時には9億1,820万米ドルに達すると予測されます。Kuvan Drugセグメントの成長率は、分析期間中CAGR 6.6%と推定されます。

米国市場は2億6,560万米ドルと推定、中国はCAGR11.2％で成長予測

米国のフェニルケトン尿症治療市場は2023年に2億6,560万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR11.2％を追いかけ、2030年までに3億4,390万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.0％と6.9％と予測されています。欧州では、ドイツがCAGR 4.4%で成長すると予測されています。

世界のフェニルケトン尿症治療市場- 主要動向と促進要因まとめ

フェニルケトン尿症（PKU）は、アミノ酸フェニルアラニンの代謝に必要な酵素フェニルアラニン水酸化酵素（PAH）の欠損によって引き起こされるまれな遺伝性代謝疾患です。PAHが欠損または欠乏すると、フェニルアラニンが血液中や脳内に蓄積し、放置すると重度の認知障害や神経学的問題を引き起こします。PKUの管理の基本は、従来、高タンパク食品を排除し、特別に処方された医療用食品とフェニルアラニンを含まないアミノ酸サプリメントを摂取する、フェニルアラニンを低く抑えた厳格な生涯にわたる食事療法でした。新生児スクリーニングプログラムによる早期診断は、未治療のPKUに伴う重篤な転帰を防ぐ上で極めて重要であり、食事療法を適時に開始し、フェニルアラニン濃度を注意深く監視することができます。

近年、PKU治療における進歩は食事管理だけにとどまらず、患者の転帰と生活の質を改善する新たな治療選択肢を提供しています。重要な進歩の1つは、補酵素であるテトラヒドロビオプテリン（BH4）の合成型であるサプロプテリン二塩酸塩のような薬理学的治療の使用であり、これは軽度から中等度のPKU患者の一部においてPAHの残存活性を増強することができます。さらに、酵素補充療法であるペグバリアーゼは、食事管理にもかかわらず血中フェニルアラニン濃度がコントロールできない成人のPKU患者に対して承認されています。ペグバリアーゼは、血中のフェニルアラニンを分解することで効果を発揮し、食事療法だけではフェニルアラニン濃度を低く維持することが困難な患者にとって、新たな治療法となります。遺伝子治療やその他の革新的な治療法も研究中で、PKUの根本的な遺伝的原因に対処することで、より永続的な解決策を提供することを目指しています。

フェニルケトン尿症治療市場の成長は、いくつかの要因によって牽引されています。ヘルスケアプロバイダーや患者の間でPKUに対する認識や理解が深まり、より早期かつ正確な診断が行われるようになり、効果的な治療に対する需要が高まっています。技術の進歩や継続的な研究により、新しい薬理療法や革新的な治療法の開発が促進され、PKU管理に利用可能な選択肢が拡大しています。また、個人の遺伝子プロファイルに合わせて治療を行う個別化医療の台頭も、より的を絞った効果的な治療を提供することで市場の成長を後押ししています。さらに、世界の新生児スクリーニングプログラムの拡大により、PKUの検出率が上昇し、包括的な治療ソリューションの必要性がさらに高まっています。特殊な医療用食品やサプリメントが入手しやすくなっていることに加え、ヘルスケア政策や希少疾患治療への資金援助も相まって、良好な市場環境が形成されています。こうした動向が進化を続ける中、フェニルケトン尿症治療市場は、医学の進歩や患者の予後改善への関心の高まりに牽引され、大きな成長を遂げようとしています。

調査対象企業の例（全86件）

  • Ajinomoto Cambrooke, Inc.
  • American Gene Technologies Inc.
  • Arla Foods Ingredients Group P/S
  • BioMarin Pharmaceutical, Inc.
  • Codexis, Inc.
  • Metropolis Healthcare Ltd.
  • Nestle Health Science SA
  • Nutricia
  • PTC Therapeutics
  • SOM Biotech
  • Synlogic
  • Travere Therapeutics, Inc.
  • Ultragenyx Pharmaceutical, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26674

Global Phenylketonuria Treatment Market to Reach US$1.6 Billion by 2030

The global market for Phenylketonuria Treatment estimated at US$975.0 Million in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2023-2030. Palynziq Drug, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$918.2 Million by the end of the analysis period. Growth in the Kuvan Drug segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$265.6 Million While China is Forecast to Grow at 11.2% CAGR

The Phenylketonuria Treatment market in the U.S. is estimated at US$265.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$343.9 Million by the year 2030 trailing a CAGR of 11.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Phenylketonuria Treatment Market - Key Trends and Drivers Summarized

Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by a deficiency in the enzyme phenylalanine hydroxylase (PAH), which is necessary for the metabolism of the amino acid phenylalanine. When PAH is deficient or absent, phenylalanine accumulates in the blood and brain, leading to severe cognitive impairments and neurological issues if left untreated. The cornerstone of PKU management has traditionally been a strict, lifelong diet low in phenylalanine, which involves the exclusion of high-protein foods and the inclusion of specially formulated medical foods and phenylalanine-free amino acid supplements. Early diagnosis through newborn screening programs has been critical in preventing the severe outcomes associated with untreated PKU, allowing for the timely initiation of dietary management and close monitoring of phenylalanine levels.

In recent years, advances in PKU treatment have expanded beyond dietary management, providing new therapeutic options that improve patient outcomes and quality of life. One significant development is the use of pharmacological treatments such as sapropterin dihydrochloride, a synthetic form of the cofactor tetrahydrobiopterin (BH4), which can enhance the residual activity of PAH in some patients with mild to moderate PKU. Additionally, pegvaliase, an enzyme substitution therapy, has been approved for adults with PKU who have uncontrolled blood phenylalanine levels despite dietary management. Pegvaliase works by breaking down phenylalanine in the bloodstream, offering a new avenue for those who struggle to maintain low phenylalanine levels through diet alone. Gene therapy and other innovative treatments are also under investigation, aiming to provide more permanent solutions by addressing the underlying genetic cause of PKU.

The growth in the phenylketonuria treatment market is driven by several factors. The increasing awareness and understanding of PKU among healthcare providers and patients have led to earlier and more accurate diagnoses, boosting the demand for effective treatments. Technological advancements and ongoing research have facilitated the development of new pharmacological therapies and innovative treatments, expanding the options available for PKU management. The rise of personalized medicine, which tailors treatments to individual genetic profiles, is also driving market growth by offering more targeted and effective therapies. Additionally, the expansion of newborn screening programs globally has increased the detection rates of PKU, further fueling the need for comprehensive treatment solutions. The growing availability of specialized medical foods and supplements, coupled with supportive healthcare policies and funding for rare disease treatments, are creating a favorable market environment. As these trends continue to evolve, the phenylketonuria treatment market is poised for significant growth, driven by advancements in medical science and a heightened focus on improving patient outcomes.

Select Competitors (Total 86 Featured) -

  • Ajinomoto Cambrooke, Inc.
  • American Gene Technologies Inc.
  • Arla Foods Ingredients Group P/S
  • BioMarin Pharmaceutical, Inc.
  • Codexis, Inc.
  • Metropolis Healthcare Ltd.
  • Nestle Health Science SA
  • Nutricia
  • PTC Therapeutics
  • SOM Biotech
  • Synlogic
  • Travere Therapeutics, Inc.
  • Ultragenyx Pharmaceutical, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Phenylketonuria Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Awareness and Understanding of PKU Expands Addressable Market Opportunity
    • Advances in Pharmacological Treatments Strengthen Business Case for PKU Management
    • Rise of Personalized Medicine Propels Growth in Tailored Therapeutics
    • Expansion of Newborn Screening Programs Generates Demand for Early Intervention
    • Development of Enzyme Substitution Therapies Drives Adoption of New Treatments
    • Innovative Gene Therapy Research Throws the Spotlight on Potential Cure for PKU
    • Technological Advancements in Medical Foods and Supplements Accelerate Market Growth
    • Growing Availability of Specialized Medical Foods Spurs Market Demand
    • Rising Investment in Rare Disease Research Generates New Opportunities
    • Focus on Long-Term Health Outcomes Strengthens Case for Comprehensive Treatment Plans
    • Integration of Telehealth Services in PKU Management Propels Market Growth
    • Increasing Prevalence of PKU and Early Diagnoses Generate Demand for Advanced Therapies
    • Advances in Biotechnology Facilitate Development of Next-Generation PKU Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Phenylketonuria Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Phenylketonuria Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Palynziq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Palynziq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Palynziq by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Kuvan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Kuvan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Kuvan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • CHINA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Phenylketonuria Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Phenylketonuria Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • INDIA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Phenylketonuria Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Phenylketonuria Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION